Date: 2016-09-01
Type of information: Nomination
Compound:
Company: Novo Nordisk (Denmark)
Therapeutic area: Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 1, 2016, Novo Nordisk announced that Lars Rebien Sørensen, president and chief executive officer, will retire from the company by the end of 2016. Lars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development, will succeed him, effective 1 January 2017. Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, US and Japan. In 2004 he was appointed senior vice president for IT & Corporate Development. In January 2013 he was appointed executive vice president and chief information officer assuming responsibility for IT, Quality & Corporate Development. In November 2014 he took over additional responsibilities for Corporate People & Organisation and Business Assurance. Lars Fruergaard Jørgensen is chairman of the Board of NNE Pharmaplan A/S, Denmark. He earned an MSc in Finance and Business Administration from Aarhus School of Business, Aarhus University, Denmark, in 1991. He is a Danish national, born November 1966. The boards of the Novo Nordisk Foundation and the Foundation's holding company, Novo A/S, will nominate Lars Rebien Sørensen to become a member of the two boards in March 2017. Novo Nordisk also announced a number of other executive-level changes, effective immediately.
Jakob Riis, currently executive vice president and head of Region China, Pacific & Marketing, is appointed executive vice president and head of North America Operations. He succeeds Jesper Høiland, who steps down from Executive Management and whose future role in Novo Nordisk will be announced at a later date.
Maziar Mike Doustdar, currently executive vice president and head of International Operations, continues in this role, but with enlarged responsibility for an expanded International Operations unit, now covering all territories except for North America and organised in the following five regions: Europe; Latin America; Africa, Asia, Middle East & Oceania; Japan & Korea; and Region China.
Jerzy Gruhn, currently executive vice president and head of Europe, steps down from Executive Management and will continue as head of Europe, now as senior vice president, reporting to Maziar Mike Doustdar.
With these changes, the members of Novo Nordisk's Executive Management are:
Lars Rebien Sørensen, president and CEO (until 31 December 2016)
Lars Fruergaard Jørgensen, EVP, Corporate Development (president and CEO as from 1 January 2017)
Jesper Brandgaard, EVP, chief financial officer
Maziar Mike Doustdar, EVP, International Operations
Jakob Riis, EVP, North America Operations
Mads Krogsgaard Thomsen, EVP, chief science officer
Henrik Wulff, EVP, Product Supply
Lars Fruergaard Jørgensen's successor as head of Corporate Development will be announced at a later date.
Financial terms:
Latest news:
